Abstract 1442P
Background
We previously reported that intratumoral HER2 heterogeneity was associated with limited treatment efficacy to trastuzumab-based chemotherapy for HER2 positive advanced gastric cancer (AGC). In this study, we investigated the mechanism of resistance associated with intratumoral HER2 heterogeneity through ctDNA analysis.
Methods
We enrolled tissue-confirmed HER2 positive AGC patients who received chemotherapy with anti-HER2 and anti-PD-1 dual-targeted therapy from a phase Ib clinical trial. We compared clinical characteristics, gene alterations that obtained by ctDNA panel (Guardant 360®), and clinical outcomes of chemotherapy with the dual targeted therapy according to the intratumor HER2 heterogeneity status.
Results
Somatic alterations in ctDNA were detected in 20 of 21 (95.2%) patients. Among them, HER2-homo was observed in 8 of 20 patients (40.0%). AGC patients with HER2-homo tended to have a higher proportion of immunohistochemistry 3+ than those with HER2-hetero (100% vs 58.3%, P = 0.055), and the ERBB2 copy number variant (CNV) detection rate in HER2-homo tended to be higher than those in HER2-hetero (87.5% vs 41.7%, P = 0.07). In addition, ctDNA ERBB2 copy number in HER2-homo was significantly higher than those in HER2-hetero (4.5 copies vs 2.51 copies, P = 0.045). In contrast, the proportion of single nucleotide variant (SNV)s or CNVs associated with the cell cycle tended to be lower in HER2 homo than in HER2 hetero (25% vs 75%, P = 0.065). Regarding clinical outcomes of chemotherapy with HER2 and PD-1 dual targeted therapy, both median progression free survival (PFS) and overall survival (OS) in the HER2-homo was tended to be longer than that in the HER2-hetero (PFS: 20.8 months [95% CI] 8.4–NA] vs. 11.3 months [95% CI 5.5–16.3]; hazard ratio (HR) 0.36; 95% CI 0.11–1.24; P = 0.1, OS: NA [95% CI 14–NA] vs. 21.0 months [95% CI 10–NA]; HR 0.36; 95% CI 0.06–1.98; P = 0.24).
Conclusions
Intra-tumor HER2 heterogeneity, classified to homogenous or heterogenous, may be a useful biomarker associated with distinct tumor biology to predict the clinical efficacy of anti-HER2 and anti- PD-1 dual targeted therapy in patients with HER2 positive AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1446P - Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
Presenter: Huiwen Miao
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
Resources:
Abstract
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
Resources:
Abstract
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
Resources:
Abstract
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
Resources:
Abstract
1451P - Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study
Presenter: Kohei Shitara
Session: Poster session 18
Resources:
Abstract
1452P - Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
Presenter: Wei Huang
Session: Poster session 18
Resources:
Abstract
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
Resources:
Abstract
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18
Resources:
Abstract
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract